Healthcare / BiotechnologyHKSE
$16.42
-0.08 (-0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-187.9M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
10.1x
↓EV/EBITDA
9.3x
↓ROE
45.3%
↑Gross Margin
88.5%
↑Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
48.6%
FCF / Net income
1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $807.0M · net income $314.4M · FCF $392.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $807.0M | $807.0M | $158.8M | — | — |
| Net Income | $314.4M | $314.4M | $-335.6M | $-507.7M | $-298.2M |
| EBITDA | $358.7M | $358.7M | $-293.7M | $-472.2M | $-263.1M |
| EPS | — | — | -1.53 | -2.29 | -1.34 |
| Gross Margin | 88.5% | 88.5% | 58.1% | — | — |
| Operating Margin | 41.3% | 41.3% | -215.5% | — | — |
| Net Margin | 39.0% | 39.0% | -211.3% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 2.30 | 1.17 | 0.46 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $392.2M | $392.2M | $-187.9M | $-308.6M | $-248.0M |
| Returns | |||||
| ROE | 45.3% | 45.3% | -146.6% | -172.3% | -46.5% |
| Valuation | |||||
| P/E | 10.07 | 10.07 | — | — | — |
| EV/EBITDA | 9.26 | 9.26 | — | — | — |
| P/B | 5.34 | 5.34 | 6.71 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 408.2% | 408.2% | — | — | — |
| EPS Growth | — | — | 33.1% | -70.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+46.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.53 → n/d
Residual
+46.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.